RECURSION PHARMACEUTICALS, INC. Federal Income Tax Expense (Benefit), Continuing Operations
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Federal Income Tax Expense (Benefit), Continuing Operations of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2025-11-05
- RECURSION PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for the quarter ending 2025-09-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for the quarter ending 2025-06-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for the quarter ending 2025-03-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for the quarter ending 2024-09-30 was $0.00.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 3 month | Federal Income Tax Expense (Benefit), Continuing Operations 6 month | Federal Income Tax Expense (Benefit), Continuing Operations 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-05 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |